Hillhouse Capital Leads Series C Round In Chinese Medical Device Developer Brosmed

China Money AI
July 27, 2020 — 16:08 CST

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Related Topics: China china healthcare chinese Dongguan Expansion guangdong healthcare Hillhouse Capital Hillhouse Capital Group japan Made in China Manufacturer Private Equity Renminbi technology United States venture capital

Related News:

Bahrain’s Investcorp Targets RMB2-4 Billion Buyout Fund in China

November 25, 2023 — 00:58

Middle Eastern Sovereign Wealth Funds Deepen Investment in China

November 10, 2023 — 23:35

AI-Driven Pharmaceutical Startups Attract Soaring Investor Interest

November 5, 2023 — 03:24

Yufeng Capital: Expect To Live To 120 Years As China Realizes Digital Healthcare

April 24, 2021 — 04:25

China, With 1.4 Billion People, Faces Looming Demographic Crisis

February 18, 2021 — 04:48

What Are China’s Tech Giants: Alibaba, Tencent, Baidu, JD, Doing In Internet Healthcare?

January 30, 2021 — 05:58

Sequoia China Leads $150 Million Round In Drug Developer Visen Pharma

January 13, 2021 — 08:47

Trustbridge Partners Leads $500 Million Round In Digital Healthcare Firm Dingxiangyuan

December 29, 2020 — 05:43

Tencent, Jeneration Capital Leads RMB2 Billion Round In Medbanks

December 22, 2020 — 04:08

Franchising and Licensing Asia (FLAsia) 2024